OBJECTIVES: To assess the independent prognostic role of histological subtypes, tumour size and lymph nodal involvement upon survival in lung neuroendocrine tumours (NETs).
INTRODUCTION
Neuroendocrine tumours (NETs) of the lung are considered a distinct subset of lung cancers, which share morphological, ultrastructural, immunohistochemical and molecular characteristics as suggested by the most recent Neuroendocrine Lung Tumours classification by Travis et al. [1] . There are four major categories of morphologically recognizable NETs, ranging from 'similar to benign forms' (typical carcinoids-TCs) to highly aggressive, poorly differentiated tumours (small-cell lung cancers-SCLCs and largecell neuroendocrine carcinomas-LCNCs). Among them, the intermediate-grade atypical carcinoids (ACs), if compared with TCs, are characterized by a higher biological aggressiveness, with a significant reduced 5-year survival and a higher tendency to lymph nodal spread at presentation.
Several authors [2] [3] [4] [5] pointed out that the spectrum of biological tumour behaviour should be considered a primary prognostic factor and should guide possible surgical and/or induction/ adjuvant treatment.
Numerous papers have recently been published regarding TC and AC surgical treatment; however, very few articles compare the outcomes of different NET subtypes and the most relevant prognostic factors [6, 7] .
The aim of this study is to describe the overall behaviour of all surgically treated NETs in our institution during the past 15 years, and to assess whether, in addition to the cell type, tumour size and nodal involvement are still important and independent factors influencing prognosis. a NET of the lung. Ours is a high-volume referral surgical and oncological institution involved in the multimodal management of primary lung cancers.
We retrospectively selected all patients submitted to surgery with a radical intention and a final histological diagnosis of TC, AC, LCNC or SCLC in the period between January 1995 and December 2011.
The main endpoints of this study are overall survival (OS) and progression-free survival (PFS).
Information collected at the time of diagnosis included electrocardiogram, lung functional test, bronchoscopy and a complete radiological work-up with total body computed tomography (CT). If clinically required, magnetic resonance was performed. In case of a peripherally located nodule, transthoracic fine-needle aspiration biopsy was often performed. Perfusion lung scanning and echocardiography were requested when a major surgical procedure was planned. Outcome data were obtained from hospital records, ambulatory controls or telephone interviews. The survival follow-up was updated for all patients in April 2013 through contacts with the municipalities of residence (only 1 patient, a LCNC case, could not be found).
Posterolateral or anterolateral thoracotomies were the standard surgical approaches, and the extent of the surgical resection was planned on the basis of the tumour's local growth and lung parenchyma condition. Bronchial sleeve resections were performed whenever feasible, and frozen sections of bronchial margins were executed in all bronchoplastic procedures. Sublobar resections (especially segmental ones) were performed when patients were functionally at high risk of lobectomy.
Systematic lymphadenectomy was performed in the majority of patients. Surgery was considered radical if a complete tumour resection (R0) was achieved and incomplete in case of micro/macroscopic residuals (R1-R2).
For the present study, two expert pathologists reviewed all histological sections and achieved a definitive diagnosis of 'neuroendocrine tumour' and its differentiation in TC, AC, LCNC and SCLC according to the Travis histological guidelines for NET diagnosis [2] . Patients with a mixed (neuroendocrine and nonneuroendocrine) histology were excluded from the study. Tumour staging was reviewed according to the 2009 IASLC/UICC Staging System (7th Edition) [8] .
Statistical analysis
Continuous data are presented as median (interquartile range (IQR)) and categorical data as frequency (%). Probabilities of time-to-event endpoints were estimated by the Kaplan-Meier method. OS was calculated from the date of intervention to the date of death from any cause, or to the last available follow-up; PFS was calculated from the date of intervention to the date of local recurrence, or distant metastases, or death from any cause, or to the last available follow-up. We performed both univariable and multivariable analyses using the Cox proportional hazard regression model to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for histological subtypes and for a list of other predefined factors (age, sex and stage; Model I). Stage was also analysed in separate models of the T and N components of TNM classification (Model II) or using tumour size (in cm) and lymph nodal involvement (Model III).
To prevent biased results due to the exclusion of a few patients with some missing variables, we did an imputation of missing values using the hotdeck procedure, where missing values were replaced by random values from the same variable, using the Schonlau implementation for the Stata software [9] . Hotdeck imputation has the advantage of being simple to use, it preserves the distributional characteristics of the variable and performs nearly as well as the more sophisticated imputation approaches [10] . STATA SE version 11.0 (StataCorp LP, TX, USA) was used for all analyses.
RESULTS

Clinical presentation and histological classification
One hundred and fifty-seven patients (82 males, 52.2%, median age 65 years) were included in this study. The characteristics of this group of patients are reported in Table 1 .
Histologically, 71 TCs (45.2%), 35 ACs (22.3%), 37 LCNCs (23.6%) and 14 SCLCs (8.9%) were observed. In 101 cases (64.3%), the tumour was a peripheral nodule.
Nine paraneoplastic syndromes were observed (3 acromegaly, 2 encephalitis, 1 Cushing syndrome, 2 flushing syndromes and 1 myasthenia gravis) in TCs and ACs. No paraneoplastic syndromes were observed in patients with LCNC or SCLC.
Surgical and adjuvant treatment
An anatomical resection was performed in all but 15 cases (atypical resections). Lobectomy was the most frequent intervention (126 cases, 80.3%; 5 sleeves). Ten patients were submitted to a bilobectomy and 6 to a pneumonectomy.
Hilar and mediastinal systemic lymphadenectomy was the standard of care; only in 9 cases (5.7%), it could not be accomplished.
Postoperative complications included atrial fibrillation in 2 cases (2 pneumonectomies), pneumonia in 2, severe respiratory insufficiency in 4 (1 patient required prolonged intensive care unit recovery), stroke in 1, prolonged pleural effusion in 3 and prolonged air leaks in 5.
No postoperative mortality was registered. Thirty-seven patients (24.0%, 5 TCs, 8 ACs, 14 LCNCs and 10 SCLCs) underwent adjuvant therapy (chemo/radio/biological therapy).
Chemotherapy was managed by our Medical Oncologist team. Generally, cisplatin/etoposide-based regimens were reserved to intermediate-/high-grade tumours, while a biological treatment with Somatostatin analogues was proposed in some TCs/ACs.
Overall and progression-free survival
The median follow-up was 6.5 years (8.0 IQR). At the end of the follow-up, 60 patients died (9 TCs, 18 ACs, 23 LCNCs and 10 SCLCs) and 73 either experienced a local/distant relapse or died. Table 2 summarizes patient outcomes according to the histological tumour subtypes. Overall, the 5-and 10-year survival rates were 64% and 53%, respectively. The corresponding rates by histology were: TCs: 89% and 83%; ACs: 58% and 38%; LCNCs: 27% and 20%; SCLCs: 20% and 0% (Table 2 and Fig. 1 ). According to histology, similar differences were observed for PFS rates (Table 2 and Fig. 2) .
To estimate possible risk factors for death, we performed both the univariable and the multivariable analyses with the following variables: age, gender, tumour histology and stage, size (cm), T, N and stage. Results are presented in Table 3 .
The univariable analysis highlights that increasing age (P < 0.001), male gender (P = 0.008), intermediate-/high-grade tumours (LCNCs and SCLCs vs TCs) (P < 0.001), greater tumour size (P = 0.001) and presence of lymph nodal metastases (N+) (P < 0.001) are strong negative prognostic factors.
At the multivariable analysis, age (HR 1.06; 95% CI 1.03-1.09, P < 0.001), histology different from TC (AC: HR 3.77; 95% CI: 1.59-8.91, P = 0.003; LCNC: HR 7.48; 95% CI: 3.15-17.78, P < 0.001; SCLC: HR 7.72; 95% CI: 2.90-20.56, P < 0.001) and N+ disease (N2; HR 2.28; 95% CI: 1.16-4.48, P = 0.017) were the only variables confirmed to be predictors of a worse survival (Model I). Neither the T category (Model II), nor the size of tumour (Model III), showed an independent prognostic role on survival when adjusted for age, histology and N category.
Forty-four patients (28%; 8 TCs, 17 ACs, 12 LCNCs and 7 SCLCs) developed distant metastasis during the follow-up time. Median time to metastasis was 1.5 years (2.5 IQR) and was longer for the TC group. Nine patients (5.7%; 2 TCs, 3 ACs, 4 LCNCs and 0 SCLCs) developed local tumour relapse and the median time to relapse was 2.5 years (5.5 IQR): again, in the TC group, it proved to be longer. Table 4 summarizes the results of the PFS analyses. At the univariable analysis, all the considered variables showed a statistically significant association with PFS. Increasing age, histology different from TC and advanced stage (III or IV) were confirmed to be negative prognostic factors at the multivariable analysis (Model I). The N2 category was confirmed to be a strong negative predictor of PFS, while T category and tumour size did not confirm an independent role (Models II and III).
DISCUSSION
This study puts into evidence that there is a large heterogeneity in NET behaviour. In fact, TCs show a very favourable clinical behaviour and survival; ACs are intermediate-grade tumours, characterized by a more aggressive biological behaviour compared with TCs, but with a better survival if compared with high-grade tumours. In contrast, LCNCs and SCLCs are poorly differentiated and highly aggressive neoplasms.
To our knowledge, only a couple of articles present in the literature [6, 7] discuss treatment of NET clinical outcomes. Several papers focus on the biological and molecular differences between them [11] [12] [13] , and many concern TC clinical outcomes alone [14] [15] [16] [17] . Compared with the two above cited studies [6, 7] , our dataset is more recent and concerns a single institution. The limitations of our study may be attributed to the heterogeneity of treatment in a wide span of time and the small numbers for each histological subtype, indeed effecting the statistical power of the study. On the other hand, the accurate revision of all histological sections and the systematic update of the follow-up, managed through municipalities of residence, should be considered as points of strength.
Tumour histology and lymph nodal involvement were the two important variables that showed a negative impact on prognosis. As expected, LCNC and SCLC survival analyses showed an overlapping trend already described in the literature [18, 19] . On the contrary, ACs presented a halfway behaviour between TCs and poorly differentiated NETs, a described a grey zone [11] . This means a high percentage of metastasis/local recurrences and almost a halved survival at 10 years compared with TCs. ACs have been considered relatively benign forms of NETs, but they may reach the aggressiveness of the poorly differentiated and highly aggressive ones. Erroneously, TCs have been considered 'benign' tumours for several decades [20] , but actually they may present with lymph nodal metastasis or spread, even if rarely. For these tumours, our data suggest that only nodal involvement plays an independent prognostic role, while tumour size seems to be less important, unless its prevalent hilar location is considered.
An adjuvant platin/etoposide regimen of chemotherapy [21, 22] , eventually supported by mediastinal radiotherapy, is the actual standard of care for resected poorly differentiated NETs.
So far, there is a lack of information about to the rarity of these tumours and publications are based on single-centred experiences. Focusing on this particular category, joining forces between international scientific oncological and thoracic surgical societies are mandatory to achieve sufficient knowledge and increase the feasibility of promoting new therapeutic randomized trials and more evidence-based guidelines for the treatment of advanced ACs. 
